Vertex reported quarterly earnings of 15 cents per share which beat the analyst consensus estimate of 14 cents per share. The ...

We recently published 10 Stocks Taking the Worst Hit. Vertex Inc. (NASDAQ:VERX) is one of the worst-performing stocks on ...

Discover key insights from Vertex, Inc.'s Q2 2025 earnings: solid revenue growth, macro challenges, and a focus on e-invoicing opportunities.

I think that's the case with Vertex. Here are seven reasons why Vertex is a no-brainer stock to buy on the dip.

KING OF PRUSSIA, Pa. (AP) — KING OF PRUSSIA, Pa. (AP) — Vertex, Inc. (VERX) on Wednesday reported a loss of $961,000 in its second quarter. On a per-share basis, the King Of Prussia, ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...

Vertex stock nose-dived Tuesday after the biotech company said it wouldn't advance its next-generation pain drug into ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit ...

Vertex Pharmaceuticals (VRTX) posts strong Q2 earnings and revenue growth but faces a 17% stock drop after mid-stage pain drug failure. Read more here.

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $470.13, denoting a +2.54% move from the preceding trading day.

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $470.13, moving +2.54% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.06% for the ...